Daniel S. Park

Daniel S. Park

Auto-generated profile, based on publicly available information

Daniel S. Park

Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Cell
Verified
Journal Article
Closed access
RTRyan Tewhey
Ryan Tewhey
DKDylan Kotliar
Dylan Kotliar
DPDaniel S. Park
Daniel S. Park
BLBrandon Liu
Brandon Liu
SWSarah Winnicki
Sarah Winnicki
PSPardis C Sabeti
Pardis C Sabeti

22 June 2020 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JLJennifer M. Luppino
Jennifer M. Luppino
DPDaniel S. Park
Daniel S. Park
SNSon C. Nguyen
Son C. Nguyen
YLYemin Lan
Yemin Lan
ZXZhuxuan Xu
Zhuxuan Xu
EJEric F. Joyce
Eric F. Joyce
The human genome can be segmented into topologically associating domains (TADs), which have been proposed to spatially sequester genes and regulatory elements through chromatin looping. Interactions between TADs have also been suggested, presumably because of variable boundary positions across individual cells. However, the nature, extent and consequence of these dynamic boundaries remain unclear. Here, we combine high-resolution imaging with Oligopaint technology to quantify the interaction frequencies across both weak and strong boundaries. We find that chromatin intermingling across population-defined boundaries is widespread but that the extent of permissibility is locus-specific. Cohesin depletion, which abolishes domain formation at the population level, does not induce ectopic interactions but instead reduces interactions across all boundaries tested. In contrast, WAPL or CTCF depletion increases inter-domain contacts in a cohesin-dependent manner. Reduced chromatin intermingling due to cohesin loss affects the topology and transcriptional bursting frequencies of genes near boundaries. We propose that cohesin occasionally bypasses boundaries to promote incorporation of boundary-proximal genes into neighboring domains.

5 October 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RLRicardo Linares-Saldana
Ricardo Linares-Saldana
WKWonho Kim
Wonho Kim
NBNikhita A. Bolar
Nikhita A. Bolar
HZHaoyue Zhang
Haoyue Zhang
BKBailey A. Koch-Bojalad
Bailey A. Koch-Bojalad
RJRajan Jain
Rajan Jain

12 December 2011 in Oncogene
Verified
Journal Article
Open access
PDF file
SSS P Sasi
S P Sasi
XYX Yan
X Yan
HEH Enderling
H Enderling
DPD Park
D Park
HGH-Y Gilbert
H-Y Gilbert
DGD A Goukassian
D A Goukassian
Tumor necrosis factor-alpha (TNF-α) binds to two distinct receptors, TNFR1/p55 and TNFR2/p75. TNF-α is implicated in the processes of tumor growth, survival, differentiation, invasion, metastases, secretion of cytokines and pro-angiogenic factors. We have shown that TNFR2/p75 signaling promotes ischemia-induced angiogenesis via modulation of several angiogenic growth factors. We hypothesized that TNFR2/p75 may promote tumor growth and angiogenesis. Growth of mouse Lewis lung carcinoma (LLC1) and/or mouse melanoma B16 cell was evaluated in wild type (WT), p75 knockout (KO) and double p55KO/p75KO mouse tumor xenograft models. Compared with WT and p55KO/p75KO mice, growth of tumors in p75KO mice was significantly decreased (twofold) in both LLC and B16 tumors. Tumor growth inhibition was correlated with decreases in vascular endothelial growth factor (VEGF) expression and capillary density, as well as bone marrow-derived endothelial progenitor cells incorporation into the functional capillary network, and an increase in apoptotic cells in LLC xenografts. Gene array analysis of tumor tissues showed a decrease in gene expression in pathways that promote tumor angiogenesis and cell survival. Blocking p75 by short-hairpin RNA in cultured LLCs led to increases in TNF-mediated apoptosis, as well as decreases in the constitutive and TNF-mediated expression of angiogenic growth factors (VEGF, HGF, PLGF), and SDF-1α receptor CXCR4. In summary, p75 is essential for tumor angiogenesis and survival in highly vascularized murine lung tumor xenografts. Blocking p75 expression may lead to tumor regression. This may represent new and effective therapy against lung neoplasms and potentially tumors of other origin.

12 July 2023 in Nature
Verified
Journal Article
Closed access
PDF file
DPDaniel S. Park
Daniel S. Park
SNSon C. Nguyen
Son C. Nguyen
RIRandi Isenhart
Randi Isenhart
PSParisha P. Shah
Parisha P. Shah
WKWonho Kim
Wonho Kim
EJEric F. Joyce
Eric F. Joyce

1 October 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
WJWon Jin Jeon
Won Jin Jeon
DPDaniel Park
Daniel Park
FAFarris Al-Manaseer
Farris Al-Manaseer
YCYi-Jen Chen
Yi-Jen Chen
JKJae Kim
Jae Kim
DCDani Ran Castillo
Dani Ran Castillo
Importance: Existing clinical trials favor neoadjuvant chemoradiation therapy (NCRT) followed by surgery alone for locally advanced esophageal cancer (EC) and perioperative chemotherapy as the preferred modality for esophageal adenocarcinoma (EAC). However, it is unclear whether these trial findings are reflected in the patterns of care and survival outcomes among patients in the clinical setting.Objective: To investigate survival outcomes in the clinical setting among patients with EC after various treatment modalities.Design, Setting, and Participants: This retrospective cohort study examined data from the National Cancer Database maintained by the American College of Surgeons and focused on patients with clinical stage II or III EC, excluding those with gastroesophageal junction cancer, who underwent trimodality therapy (NCRT followed by esophagectomy), definitive chemoradiation therapy (DCRT), radiotherapy (RT) alone, or perioperative chemotherapy from January 2006 to December 2020. Analyses were conducted from December 2023 to August 2024.Exposures: Perioperative chemotherapy, trimodality therapy, DCRT, and single-modality RT.Main Outcomes and Measures: A Cox proportional hazards regression model was used to compare overall survival (OS) between treatment groups in the entire cohort, among patients with squamous cell carcinoma or adenocarcinoma, and among those older than 65 years. Landmark survival analysis at 6 months was performed to reduce survivorship bias.Results: The study included 57 116 patients (median age, 64 [IQR, 57-72] years; 45 410 [79.5%] male); 21 619 patients (37.9%) received trimodality therapy, 32 493 (57.1%) received DCRT, 2692 (4.7%) received single-modality RT, and 312 (0.5%) received perioperative chemotherapy. In the overall study population, 37 698 patients (66.0%) had EAC, and of the 312 patients that received perioperative chemotherapy, 283 (90.7%) had EAC. In adjusted survival analysis, perioperative chemotherapy (adjusted hazard ratio [AHR], 0.33; 95% CI, 0.28-0.39; P <.001) and trimodality therapy (AHR, 0.45; 95% CI, 0.44-0.46; P < .001) were associated with improved OS compared with DCRT. In contrast, RT alone was associated with worse outcomes compared with DCRT (AHR, 1.37; 95% CI, 1.30-1.45; P < .001). The median OS for perioperative chemotherapy of 66.2 months (95% CI, 43.1-111.9 months; P < .001) was longer compared with that for DCRT alone (18.1 months; 95% CI, 17.8-18.4 months; P < .001). Trimodality therapy was associated with a median OS of 43.9 months (95% CI, 42.8-45.5 months; P < .001), which was shorter than that for perioperative chemotherapy but improved compared with DCRT and RT alone, which was associated with a median OS of 13.5 months (95% CI, 12.8-14.0 months; P < .001). In the subgroup of patients older than 65 years, those who received perioperative chemotherapy had longer median OS (56.7 months; 95% CI, 36.4-115.2 months; P < .001) compared with those receiving other treatment modalities (eg, trimodality therapy: 40.1 months; 95% CI, 38.1-42.0 months; P < .001). Patients who received RT alone had the worst median OS (13.6 months; 95% CI, 12.8-14.4 months; P < .001).Conclusions and Relevance: In this cohort study of patients with stage II to III EC, trimodality therapy was associated with improved OS compared with DCRT or RT alone for locally advanced EC and perioperative chemotherapy was associated with improved OS for adenocarcinoma.